Evidence map›Paper›PMID 28177881›Full record

ArticleOncotarget2017

A panel of microRNA signature in serum for colorectal cancer diagnosis.

Mingxia Zhu, Zebo Huang, Danxia Zhu, Xin Zhou, Xia Shan, Lian-Wen Qi, Lirong Wu, Wenfang Cheng, Jun Zhu, Lan Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Dysregulated miRNAs Targeting Adiponectin Signaling in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mingxia ZhuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zebo HuangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Danxia ZhuDepartment of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Xin ZhouDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Xia ShanDepartment of Respiration, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210009, China.
Lian-Wen QiState Key Laboratory of Natural Medicines and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, 210009, China.
Lirong WuDepartment of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China.
Wenfang ChengDepartment of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jun ZhuDepartment of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China.
Lan ZhangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Huo ZhangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Yan ChenDepartment of Emergency, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Wei ZhuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Tongshan WangDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Ping LiuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulated expression of specific microRNAs (miRNAs) in serum has been recognised as promising diagnostic biomarkers for colorectal cancer (CRC). In the initial screening phase, a total of 32 differentially expressed miRNAs were selected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel with 3 CRC pool samples and 1 normal control (NC) pool. Using qRT-PCR, selected serum miRNAs were further confirmed in training (30 CRC VS. 30 NCs) and testing stages (136 CRC VS. 90 NCs). We identified that serum levels of miR-19a-3p, miR-21-5p and miR-425-5p were significantly higher in patients with CRC than in NCs. The areas under the receiver operating characteristic (ROC) curve of the three-miRNA panel were 0.86, 0.74 and 0.87 for the training, testing and the external validation stages (30 CRC VS. 18 NCs), respectively. Significantly, elevated expression of the three miRNAs was also observed in CRC tissues (n = 24). Furthermore, the expression levels of the three miRNAs were significantly elevated in exosomes from CRC serum samples (n = 10). In conclusion, we identified a serum three-miRNA panel for the diagnosis of CRC.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorColorectal NeoplasmsFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedReverse Transcriptase Polymerase Chain ReactionROC CurveBiomarkers, TumorMicroRNAsMIRN19A microRNA, humanMIRN21 microRNA, humanMIRN425 microRNA, humancolorectal cancerdiagnostic biomarkerqRT-PCRserum microRNA

Identifiers

PMID28177881
PMCPMC5370024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.